Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07771361 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07771361 · ClinicalTrials.gov record · last posted 2026-08-18

BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

StatusNot Yet Recruiting
PhasePhase 2
Started2026-12
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against relapsed or refractory B cell non-Hodgkin lymphoma and multiple myeloma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This Phase 2 study will establish the safety and efficacy profile of LMY-920.
Trial Details
NCT Number NCT07771361
Lead Sponsor Luminary Therapeutics
Conditions Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin Lymphoma, B-cell, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma in Remission
Enrollment 90 participants
Start Date 2026-12
Primary Completion 2030-12 (estimated)
Study Completion 2031-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-18